Cytokinetics Inc vs Southwest Airlines Co — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Southwest Airlines Co trades at $45.71 (market cap $21.97B). The key difference: Southwest Airlines Co is far larger — about 2× Cytokinetics Inc's market cap, and Southwest Airlines Co pays a 1.6% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LUV | |
|---|---|---|
Market Cap | $10.78B | $21.97B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $54.80 |
52-Week Low | $34.31 | $29.67 |
Enterprise Value | $10.88B | $25.06B |
Dividend Yield | — | 1.6% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Southwest Airlines (LUV) trades at $47.05, up 0.23% today, with a bullish technical signal and consensus price target of $53.86. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, driven by record revenue. The company maintains a solid liquidity position of $8.73B cash and has declared quarterly dividends of $0.18 per share, with new board appointments signaling strategic focus.
Outlook is positive with projected 2026 net income margin of 2.78% and revenue growth to $30.1B, but risks include fuel cost volatility and competitive pressures. Analyst sentiment is mixed with 42% buy ratings, offering potential upside of 14.5% to the consensus target, though institutional selling by firms like Elliott Management warrants monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →